WHY IT MATTERS: If you use cannabis and notice yourself reaching for specific types of snacks, understanding that this is a predictable physiological response can help you plan ahead with healthier options and avoid unwanted weight gain during treatment. CLINICAL OVERVIEW: New clinical trial data examining cannabis-induced appetite changes confirms what many patients report in practice: cannabis alters not just hunger levels but specific food preferences, particularly toward calorie-dense, palatable options rich in fats and sugars. This research is clinically relevant because understanding munchies at a mechanistic level helps physicians counsel patients on dietary planning, weight management, and nutritional strategies when cannabis is part of their treatment regimen.
DOH sets conditions on proposed medical cannabis legalization | Philippine News Agency
WHY IT MATTERS: If the Philippines establishes a regulated medical cannabis program, patients in the country who currently have no legal access to cannabinoid therapies for conditions like chronic pain, epilepsy, or cancer-related symptoms could gain physician-supervised treatment options through a formal compassionate access pathway. CLINICAL OVERVIEW: The Philippine Department of Health is establishing conditions for a proposed medical cannabis legalization framework that would include compassionate access pathways for patients alongside expanded research initiatives and formal regulatory oversight. This approach mirrors the structured medical cannabis programs that have been successfully implemented in dozens of countries worldwide, where physician-supervised access is paired with robust safety monitoring.
Study Finds Veterans With SUD Used Cannabis to Alleviate Pain, Anxiety, and Improve Poor …
WHY IT MATTERS: If you are a veteran managing pain, anxiety, or sleep issues alongside a substance use disorder, this research supports having an honest conversation with your care team about whether supervised cannabis use could be a safer part of your recovery plan. CLINICAL OVERVIEW: New research examining veterans with substance use disorders found that many turned to cannabis to manage pain, anxiety, and sleep disturbances during their treatment for non-cannabis-related SUD. This aligns with what we see clinically, where patients often use cannabis as an adjunct or alternative to more harmful substances, particularly opioids and benzodiazepines.
Cannabis hyperemesis syndrome cases surge in Virginia ERs – YouTube
WHY IT MATTERS: If you use cannabis regularly and experience recurring nausea, vomiting, or abdominal pain that temporarily improves with hot showers, you should talk to your cannabis clinician about adjusting your dose, frequency, or product potency before your next ER visit. CLINICAL OVERVIEW: Cannabis hyperemesis syndrome (CHS) is a real clinical condition characterized by cyclical vomiting, nausea, and abdominal pain in frequent cannabis users, and emergency departments across legalized states are reporting increased presentations. While CHS can be distressing and even dangerous if dehydration becomes severe, it is almost always associated with very high-frequency, high-potency use and resolves reliably with cessation or significant dose reduction.
The House Committee on Dangerous Drugs, together with the Committee on Health … – Facebook
WHY IT MATTERS: When countries like the Philippines move toward legalizing medical cannabis, it expands the global research landscape and may eventually improve the quality and diversity of clinical evidence that informs treatment protocols everywhere, including for patients currently under care. CLINICAL OVERVIEW: The Philippine House of Representatives is advancing legislative efforts through its committees on dangerous drugs and health to establish a medical cannabis framework for qualified patients, including a regulatory system and provisions for further research into therapeutic applications. This type of legislative movement in Southeast Asia reflects a broader global trend of countries reevaluating restrictive cannabis policies in light of mounting clinical evidence supporting cannabinoid therapies for conditions like chronic pain, epilepsy, and chemotherapy-induced nausea.
Are My THC Gummies Going Away? – Science Friday
WHY IT MATTERS: If federal law changes to restrict hemp-derived THC gummies and similar products, patients currently using them for pain, sleep, or anxiety may need to transition to state-regulated medical cannabis programs or lose access to their current therapies entirely. CLINICAL OVERVIEW: The legal status of THC gummies derived from hemp is under increasing scrutiny as federal lawmakers consider closing the loophole created by the 2018 Farm Bill that allowed hemp-derived THC products to flood the consumer market. From a clinical standpoint, many patients have come to rely on these accessible, legal THC products for symptom management, particularly in states without robust medical cannabis programs.
America Doesn’t Have A ‘Marijuana Problem,’ As NYT Claims—It Has a Cannabis Education …
WHY IT MATTERS: When media and policymakers frame cannabis use as a “problem” rather than an education gap, it slows the development of clinical programs, physician training, and insurance coverage that patients need to access safe, guided care. CLINICAL OVERVIEW: The framing of cannabis as a “marijuana problem” in mainstream media reflects a deeper failure in clinical education, research access, and regulatory coherence rather than an inherent danger of the plant itself. Physicians are not trained in endocannabinoid medicine during medical school, research remains federally restricted, and patients are left navigating a fragmented system without proper clinical guidance.
So, What Does an Adult at Low Risk of Cannabis Dependence Look Like?
WHY IT MATTERS: If you are a current or prospective cannabis patient, understanding your personal risk factors for dependence helps you and your physician build a safer, more individualized treatment plan with appropriate monitoring. CLINICAL OVERVIEW: Understanding the risk profile for cannabis dependence is a critical clinical question that helps physicians identify which adult patients can use cannabis therapeutically with lower likelihood of developing problematic use patterns. Factors such as age of initiation, mental health history, frequency of use, genetic predisposition, and the presence of other substance use disorders all contribute to a patient’s overall risk profile.
Teen Cannabis Use Tied to Increase in Serious Mental Illness – Medscape
WHY IT MATTERS: If you are a parent or caregiver of a teen, or a young person using cannabis yourself, this research reinforces that delaying use until the brain is more fully developed, typically into the mid-20s, is one of the most important harm reduction strategies available. CLINICAL OVERVIEW: Emerging research continues to reinforce what clinicians have observed for years: adolescent cannabis use, particularly during critical neurodevelopmental windows, is associated with a meaningful increase in risk for serious psychiatric conditions including psychotic and bipolar disorders. The developing brain remains uniquely vulnerable to exogenous cannabinoids, and the endocannabinoid system plays a central role in synaptic pruning and neural circuit maturation during the teenage years.
Indiana S.B. 250 could close Lafayette hemp-beverage sales without a key amendment
WHY IT MATTERS: If Indiana S.B. 250 passes without amendment, patients in the state who use hemp-derived cannabinoid beverages for sleep, anxiety, or pain relief may lose legal access to these products entirely, forcing them to seek alternatives that may be less safe or less predictable in dosing. CLINICAL OVERVIEW: Indiana’s proposed S.B. 250 threatens to eliminate legal hemp-derived cannabinoid beverage sales in the state, which could displace patients and consumers who currently rely on these regulated products for symptom management.